Non-metastatic Castration-sensitive Prostate Cancer

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2026-01-26
Clinical Trial Update: Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer [Phase 1]
Phase 1 trial evaluating Xaluritamig in high-risk biochemically recurrent, non-metastatic castration-sensitive prostate cancer (Amgen-sponso…